Skip to content

Released May 7, 2026, before the open

10-Q filed May 7, 2026, 37 days after period end · 0001628280-26-031671

Q1 2026 · 10-Q
Revenue$3.27M−45.1% vs Q1 2025−64.7% vs Q4 2025
Net Income-$19.88MN/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.29N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$21,573,000N/M
Operating Cash Flow-$25,266,000N/M
Free Cash Flowderived-$25,266,000N/M
Margins · derived
Operating margin-660.3%−275.4 pt vs Q1 2025
Net margin-608.4%−291.9 pt vs Q1 2025

What the release said

The release

Same quarter

MetricQ1 2026Q1 2025Q1 2024Q1 2023
Revenue$3.27M$5.95M$5.05M$5.31M
Net Income-$19.88M-$18.83M-$25.02M-$30.49M
EPS Diluted-$0.29-$0.30-$0.59-$0.73

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR